Antibody Information

General Information of This Antibody

Antibody ID	ANI0ZNGSX
Antibody Name	04-046Ch
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1-kappa
Antigen Name	G-protein coupled receptor 20 (GPR20)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

WO2018135501A1 ADC-2 [Investigative]

ADC Info

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≉ 33.30% (Day 46)	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 10⁶ cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm³ mice were randomly allocated to treatment groups. The dose of ADC was 10 mg/kg, i.v.*1.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20)
Experiment 2 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≋ 87.00% (Day 52)	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 10⁶ cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm³ mice were randomly allocated to treatment groups. The dose of ADC was 10 mg/kg, qw*3.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST430)

WO2018135501A1 ADC-1 [Investigative]

ADC Info

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≊ 87.00% (Day 52)	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 10⁶ cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm³ mice were randomly allocated to treatment groups. The dose of ADC was 10 mg/kg, qw*3.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST430)
Experiment 2 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 93.60% (Day 46)	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 10⁶ cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm³ mice were randomly allocated to treatment groups. The dose of ADC was 10 mg/kg, i.v.*1.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20)

References

Ref 1	Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate; 2018-07-26.